Lumiera Health Inc. (V:NHP)
Business Focus: Pharmaceuticals (NEC)
| Sector: Healthcare | Industry: Pharmaceuticals |
| Company Contact | |
| Address: | 4500 Blvd. Kimber SAINT-HUBERT QC J3Y 8K5 |
| Tel: | N/A |
| Website: | https://www.lumiera.ca |
| IR: | See website |
| Key People | ||
| Carlos Ponce Chief Executive Officer, Director | Simon Castonguay Interim Chief Financial Officer, Director | Richard Giguere Vice President of Sales and Marketing |
| Business Overview |
| Lumiera Health Inc. is a Canada-based natural health products company. The principal business of the Company is that of selling natural and homeopathic products. The Company specializes in the development and commercialization of evidence-based botanical products for the healthcare industry. The Company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. It is also developing and commercializing a portfolio of innovative solutions in high growth categories such as sleep-aids and pain management. Its product's portfolio categories such as topical pain relief, sleep, skin care, women's health, & infections. The Company's products and brands include Holizen, Awaye pain relief cream and Bazzzics. The Holizen portfolio has over 20 products that cover a range of therapeutic needs, including cardiovascular health; stress relief; bones, joints & muscle mobility; energy and immunity. |
| Financial Overview |
| For the nine months ended 31 August 2023, Lumiera Health Inc revenues decreased 45% to $243K. Net loss applicable to common stockholders decreased 74% to $368K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Salaries and payroll decrease from $516K (expense) to $0K, Interest, accretion and bank charges decrease of 61% to $236K (expense). |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $3.42M as of Aug 31, 2023 |
| Annual revenue (TTM): | $0.59M as of Aug 31, 2023 |
| EBITDA (TTM): | -$0.71M as of Aug 31, 2023 |
| Net annual income (TTM): | -$2.36M as of Aug 31, 2023 |
| Free cash flow (TTM): | -$0.49M as of Aug 31, 2023 |
| Net Debt Last Fiscal Year: | $1.79M as of Aug 31, 2023 |
| Shares outstanding: | 169,965,217 as of Aug 31, 2023 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
